Full-Time

Key Account Manager

Confirmed live in the last 24 hours

argenx

argenx

1,001-5,000 employees

Biotechnology for autoimmune disease treatments

No salary listed

Senior, Expert

Neukirchen-Vluyn, Germany

Field based position with significant territory travel and occasional overnight stays when required.

Category
Strategic Account Management
Sales & Account Management
Requirements
  • University degree in scientific or business-related subject or equivalent qualification
  • Minimum 8-10 years of successful field experience in the biopharmaceuticals industry, partially within rare diseases and/or neurology
  • Experience within the neuromuscular field is an asset
Responsibilities
  • Proactively identify opportunities to accelerate growth of the brand VYVGART® in Germany, in partnership with the local medical team and the regional teams
  • Promote in all circumstances (remote interactions, face to face, staff meetings, congresses etc) safe and effective use of our product, in accordance with the product label to ensure that the benefits and long-term value of the product are fully understood
  • Develop, own, and drive territory and account plans, including customer targeting, in line with country strategy and in partnership with the local Medical Affairs team
  • Develop and execute on the marketing strategy and promotional initiatives including omnichannel activities for the brand VYVGART® for Germany leveraging the strategy & assets developed by the regional team
  • Develop, own and drive access plan to secure inclusion in regional and local formularies. Follow accurately all the external stakeholders involved (Hospital pharmacist, local and regional stakeholder)
  • Achieve pre-launch and post-launch KPIs, including account plans and volume targets
  • Perform detailed analysis of the assigned territory to identify, assess, and develop relevant centres for diagnosis and treatment
  • Develop trusted relationships with a portfolio of customers to ensure competitive advantage, after developing a thorough understanding of key customer needs and requirements
  • Ensure the correct products and services are delivered to customers in a timely manner by collaborating with internal stakeholders (commercial, supply chain, and compliance) and external stakeholders (hospital pharmacists, tender managers, listing committees)
  • Manage and execute local meetings for physicians and other healthcare professionals to support diagnosis and optimal treatment, in collaboration with the Medical Affairs Team
  • Timely and accurate reporting and continuous diligent maintenance of customer relationship management (CRM) tools and systems
  • Conduct all activities to highest ethical standards in accordance with country code of practice and local laws and regulations
  • Establish and maintain contact with key customers and provide commercial and scientific services to ensure access at site of care, and that logistics are in place to list, order and administer product
Desired Qualifications
  • Significant key account management experience and capabilities
  • Previous evidence of successful working in a cross-functional team
  • Ability to translate business insights into commercial action plan
  • Ability to demonstrate strong commercial focus and business acumen
  • Ability to understand and communicate high level scientific data
  • Ability to work collaboratively and effectively together within cross-functional teams and networks
  • Demonstrated communication skills, within a multi-cultural and multi-lingual global environment
  • Is agile and demonstrates adaptability, comfort with ambiguity, trust-building, and resilience
  • Derives energy from operating in a dynamic, complex, fast-moving, and frequently changing business environment
  • Demonstrable experience with project management, proactive planning, priority setting, and securing alignment
  • Drives toward outcomes
  • Ambitious, inquisitive naturally, a quick study, with demonstrated eagerness to continuously learn, self-improve and develop. This includes being comfortable giving and receiving feedback in a diverse environment.
  • Passionate and prepared to lead and contribute to our culture, which is driven by our corporate values of co-creation, innovation, empowerment, excellence, and humility.

argenx develops treatments for severe autoimmune diseases and cancer through biotechnology. The company focuses on creating therapeutic antibodies, which are proteins designed to target specific diseases. One of their main products, cusatuzumab, is being developed with Janssen R&D to treat blood cancers like leukemia. What sets argenx apart from other companies in the biopharmaceutical market is its strong emphasis on collaboration with academic institutions and industry partners to turn scientific research into effective therapies. The goal of argenx is to provide effective immunology solutions that improve the lives of patients suffering from serious health conditions.

Company Size

1,001-5,000

Company Stage

IPO

Headquarters

Ghent, Belgium

Founded

2008

Simplify Jobs

Simplify's Take

What believers are saying

  • argenx's cusatuzumab benefits from personalized medicine trends in oncology.
  • Steroid-sparing therapeutics collaboration aligns with demand for reduced side effects.
  • Advancing multiple Phase 2 trials by 2024 accelerates candidate identification.

What critics are saying

  • Increased competition in immunology may impact argenx's market share.
  • Failure of efgartigimod in pemphigus could reduce investor confidence.
  • Regulatory scrutiny on drug pricing may affect argenx's revenue streams.

What makes argenx unique

  • argenx collaborates with Janssen R&D on cusatuzumab for leukemia treatment.
  • Focus on autoimmune diseases with innovative FcRn blockers differentiates argenx.
  • Partnerships with academic institutions enhance argenx's research capabilities.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Hybrid Work Options

Growth & Insights and Company News

Headcount

6 month growth

1%

1 year growth

3%

2 year growth

1%
Stock Titan
Feb 25th, 2025
argenx to Present at TD Cowen 45th Annual Healthcare Conference

argenx, a global immunology company focused on improving lives of people with severe autoimmune diseases, has announced that Tim Van Hauwermeiren, Chief Executive Officer, will present at the TD Cowen 45th Annual Healthcare Conference.

Business Wire
Nov 22nd, 2024
OncoVerity Secures Extended Series A to Advance Cusatuzumab in Newly Diagnosed AML

Alongside financing, first patients dosed in OV-AML-1231, a Phase 2 randomized controlled trial of cusatuzumab in newly diagnosed AML

Clinical Trial Vanguard
Nov 20th, 2024
Steritas & Argenx Announce Collaboration to Advance Steroid-Sparing Therapeutics

Steritas LLC, a company focused on improving care for patients treated with steroids, has partnered with global immunology company Argenx.

BioSpace
May 9th, 2024
Argenx Reports First Quarter 2024 Financial Results And Provides Business Update

$398 million in first quarter global net product sales. FDA review ongoing for CIDP sBLA with PDUFA target action date of June 21, 2024. On track to submit filing for pre-filled syringe (PFS) in second quarter 2024

BioSpace
May 2nd, 2024
Argenx To Report First Quarter 2024 Financial Results And Business Update On May 9, 2024

Amsterdam, the Netherlands – argenx (Euronext Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today announced that it will host a conference call and audio webcast on Thursday, May 9, 2024 at 2:30 PM CET (8:30 AM ET) to discuss its first quarter 2024 financial results and provide a business update.A webcast of the live call may be accessed on the Investors section of the argenx website at argenx.com/investors. A replay of the webcast will be available on the argenx website for approximately one year following the presentation.Dial-in numbers:Belgium 32 800 50 201. France 33 800 943355. Netherlands 31 20 795 1090